









Markets
/
Stocks
/
nasdaq-bsx
/

Boston Scientific Corp

BSX

100.300USD

-0.670-0.66%

Close 10/29, 16:00（ET）Quotes delayed by 15 min

148.48BMarket Cap

53.20P/E TTM



Boston Scientific Corp

100.300

-0.670-0.66%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Boston Scientific Corp

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Boston Scientific Corp's Score

Industry at a Glance

Industry Ranking

8 / 210

Overall Ranking

54 / 4623

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 37 analysts

Buy

Current Rating

125.444

Target Price

+24.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Boston Scientific Corp Highlights

StrengthsRisks

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. It also owns the transcarotid artery revascularization (TCAR) platform.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 32.05% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 16.75B.

Undervalued

The company’s latest PE is 53.13, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.39B shares, decreasing 0.45% quarter-over-quarter.

Held by PRIMECAP Management

Star Investor PRIMECAP Management holds 34.66M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 8.65, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 5.07B, representing a year-over-year increase of 20.34%, while its net profit experienced a year-over-year increase of 60.98%.

Score

Industry at a Glance

Previous score

8.65

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Boston Scientific Corp's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 5.88, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 53.13, which is 112.84% below the recent high of 113.08 and 0.00% above the recent low of 53.13.

Score

Industry at a Glance

Previous score

5.88

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 8/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 8.67, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Boston Scientific Corp is 125.00, with a high of 140.00 and a low of 101.21.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 37 analysts

Buy

Current Rating

125.444

Target Price

+24.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

Danaher Corp

DHR

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 7.54, which is higher than the Healthcare Equipment & Supplies industry's average of 6.63. Sideways: Currently, the stock price is trading between the resistance level at 105.68 and the support level at 94.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.22

Change

-1.68

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

1.046

Buy

RSI(14)

51.723

Neutral

STOCH(KDJ)(9,3,3)

46.021

Sell

ATR(14)

2.279

Low Volatility

CCI(14)

21.855

Neutral

Williams %R

47.354

Neutral

TRIX(12,20)

0.100

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

101.440

Sell

MA10

100.850

Sell

MA20

98.651

Buy

MA50

100.986

Sell

MA100

102.290

Sell

MA200

101.815

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 93.50%, representing a quarter-over-quarter decrease of 0.07%. The largest institutional shareholder is The Vanguard, holding a total of 136.47M shares, representing 9.21% of shares outstanding, with 2.64% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

136.47M

+1.89%

Fidelity Management & Research Company LLC

99.47M

-15.31%

BlackRock Institutional Trust Company, N.A.

78.19M

+0.49%

State Street Investment Management (US)

65.19M

+1.11%

PRIMECAP Management Company

Star Investors

34.66M

-5.03%

Wellington Management Company, LLP

32.65M

-1.65%

Geode Capital Management, L.L.C.

32.42M

+1.96%

Capital World Investors

28.52M

-0.12%

Managed Account Advisors LLC

22.05M

+3.60%

The Bollard Group, LLC

20.08M

-2.01%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 9.51, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.58. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.